Heping Yang1,2, Ting Liu1,2,3, Jiaohong Wang1,2, Tony W H Li1,2, Wei Fan1,2,4, Hui Peng1,2, Anuradha Krishnan5, Gregory J Gores5, Jose M Mato6, Shelly C Lu1,2. 1. Division of Gastroenterology, Cedars-Sinai Medical Center, Los Angeles, CA. 2. USC Research Center for Liver Diseases, Keck School of Medicine USC, Los Angeles, CA. 3. Department of Gastroenterology, Xiangya Hospital Central South University, Changsha, Hunan, China. 4. Department of Geriatrics, Guangzhou First People's Hospital, Guangzhou, China. 5. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN. 6. CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Technology, Park of Bizkaia, Derio, Spain.
Abstract
UNLABELLED: c-Myc induction drives cholestatic liver injury and cholangiocarcinoma (CCA) in mice, and induction of Maf proteins (MafG and c-Maf) contributes to cholestatic liver injury, whereas S-adenosylmethionine (SAMe) administration is protective. Here, we determined whether there is interplay between c-Myc, Maf proteins, and methionine adenosyltransferase α1 (MATα1), which is responsible for SAMe biosynthesis in the liver. We used bile duct ligation (BDL) and lithocholic acid (LCA) treatment in mice as chronic cholestasis models, a murine CCA model, human CCA cell lines KMCH and Huh-28, human liver cancer HepG2, and human CCA specimens to study gene and protein expression, protein-protein interactions, molecular mechanisms, and functional outcomes. We found that c-Myc, MATα1 (encoded by MAT1A), MafG, and c-Maf interact with one another directly. MAT1A expression fell in hepatocytes and bile duct epithelial cells during chronic cholestasis and in murine and human CCA. The opposite occurred with c-Myc, MafG, and c-Maf expression. MATα1 interacts mainly with Mnt in normal liver, but this switches to c-Maf, MafG, and c-Myc in cholestatic livers and CCA. Promoter regions of these genes have E-boxes that are bound by MATα1 and Mnt in normal liver and benign bile duct epithelial cells that switched to c-Myc, c-Maf, and MafG in cholestasis and CCA cells. E-box positively regulates c-Myc, MafG, and c-Maf, but it negatively regulates MAT1A. MATα1 represses, whereas c-Myc, MafG, and c-Maf enhance, E-box-driven promoter activity. Knocking down MAT1A or overexpressing MafG or c-Maf enhanced CCA growth and invasion in vivo. CONCLUSION: There is a novel interplay between MATα1, c-Myc, and Maf proteins, and their deregulation during chronic cholestasis may facilitate CCA oncogenesis. (Hepatology 2016;64:439-455).
UNLABELLED: c-Myc induction drives cholestatic liver injury and cholangiocarcinoma (CCA) in mice, and induction of Maf proteins (MafG and c-Maf) contributes to cholestatic liver injury, whereas S-adenosylmethionine (SAMe) administration is protective. Here, we determined whether there is interplay between c-Myc, Maf proteins, and methionine adenosyltransferase α1 (MATα1), which is responsible for SAMe biosynthesis in the liver. We used bile duct ligation (BDL) and lithocholic acid (LCA) treatment in mice as chronic cholestasis models, a murineCCA model, humanCCA cell lines KMCH and Huh-28, humanliver cancerHepG2, and humanCCA specimens to study gene and protein expression, protein-protein interactions, molecular mechanisms, and functional outcomes. We found that c-Myc, MATα1 (encoded by MAT1A), MafG, and c-Maf interact with one another directly. MAT1A expression fell in hepatocytes and bile duct epithelial cells during chronic cholestasis and in murine and humanCCA. The opposite occurred with c-Myc, MafG, and c-Maf expression. MATα1 interacts mainly with Mnt in normal liver, but this switches to c-Maf, MafG, and c-Myc in cholestatic livers and CCA. Promoter regions of these genes have E-boxes that are bound by MATα1 and Mnt in normal liver and benign bile duct epithelial cells that switched to c-Myc, c-Maf, and MafG in cholestasis and CCA cells. E-box positively regulates c-Myc, MafG, and c-Maf, but it negatively regulates MAT1A. MATα1 represses, whereas c-Myc, MafG, and c-Maf enhance, E-box-driven promoter activity. Knocking down MAT1A or overexpressing MafG or c-Maf enhanced CCA growth and invasion in vivo. CONCLUSION: There is a novel interplay between MATα1, c-Myc, and Maf proteins, and their deregulation during chronic cholestasis may facilitate CCA oncogenesis. (Hepatology 2016;64:439-455).
Authors: I Pérez Mato; M M Sanchez del Pino; M E Chamberlin; S H Mudd; J M Mato; F J Corrales Journal: J Biol Chem Date: 2001-01-30 Impact factor: 5.157
Authors: Maria Lauda Tomasi; Ainhoa Iglesias-Ara; Heping Yang; Komal Ramani; Francesco Feo; Maria Rosa Pascale; M Luz Martínez-Chantar; José M Mato; Shelly C Lu Journal: Gastroenterology Date: 2008-09-25 Impact factor: 22.682
Authors: Luke Boulter; Rachel V Guest; Timothy J Kendall; David H Wilson; Davina Wojtacha; Andrew J Robson; Rachel A Ridgway; Kay Samuel; Nico Van Rooijen; Simon T Barry; Stephen J Wigmore; Owen J Sansom; Stuart J Forbes Journal: J Clin Invest Date: 2015-02-17 Impact factor: 14.808
Authors: Ben Murray; Hui Peng; Lucia Barbier-Torres; Aaron E Robinson; Tony W H Li; Wei Fan; Maria Lauda Tomasi; Roberta A Gottlieb; Jenny Van Eyk; Zhimin Lu; Maria L Martínez-Chantar; Suthat Liangpunsakul; Nicholas J Skill; José M Mato; Shelly C Lu Journal: Hepatology Date: 2019-06-25 Impact factor: 17.425